Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Amortizatization of Intangibles: 2013-2024

Historic Amortizatization of Intangibles for Tg Therapeutics (TGTX) over the last 12 years, with Dec 2024 value amounting to $7.0 million.

  • Tg Therapeutics' Amortizatization of Intangibles fell 56.74% to $786,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $5.1 million, marking a year-over-year decrease of 15.67%. This contributed to the annual value of $7.0 million for FY2024, which is 212.34% up from last year.
  • Per Tg Therapeutics' latest filing, its Amortizatization of Intangibles stood at $7.0 million for FY2024, which was up 212.34% from $2.2 million recorded in FY2023.
  • In the past 5 years, Tg Therapeutics' Amortizatization of Intangibles ranged from a high of $7.0 million in FY2024 and a low of $216,000 during FY2020.
  • Its 3-year average for Amortizatization of Intangibles is $4.0 million, with a median of $2.7 million in 2022.
  • Its Amortizatization of Intangibles has fluctuated over the past 5 years, first skyrocketed by 777.78% in 2021, then declined by 17.64% in 2023.
  • Tg Therapeutics' Amortizatization of Intangibles (Yearly) stood at $216,000 in 2020, then soared by 777.78% to $1.9 million in 2021, then surged by 43.20% to $2.7 million in 2022, then dropped by 17.64% to $2.2 million in 2023, then soared by 212.34% to $7.0 million in 2024.